The Second Affiliated Hospital of Nanjing Medical University
Welcome,         Profile    Billing    Logout  
 0 Trials 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Jin
NCT05353192: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Recruiting
4
38
RoW
Recombinant human growth hormone
GeneScience Pharmaceuticals Co., Ltd., Children's Hospital of Fudan University, Tongji Hospital, Children's Hospital of Nanjing Medical University, Jiangxi Province Children's Hospital, Chengdu Women's and Children's Central Hospital, Shandong Provincial Hospital, Shengjing Hospital, Shanghai Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics, West China Second University Hospital, Sichuan University
Achondroplasia
02/25
02/25
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Active, not recruiting
3
528
RoW
TQB2450, Anlotinib, Sunitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Renal Cancer
06/25
12/25
BHV3000-318, NCT05371652: A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

Completed
3
241
RoW
Rimegepant 75mg Orally Disintegrating Tablets (ODT)
Pfizer, Bioshin (Shanghai) Consulting Services Co., Ltd
Acute Migraine
02/24
02/24
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Recruiting
1/2
68
RoW
T3011 high dose, T3011 middle dose, T3011 low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumors
12/25
05/26
TQB2618-AK105-Ib-02, NCT05783921: A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
1/2
60
RoW
TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma
08/24
01/25
NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Recruiting
1
156
RoW
JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
Shanghai Junshi Bioscience Co., Ltd.
Melanoma, Renal Carcinoma, Urothelial Carcinoma
02/24
08/24
Lu, Yibing
RECAM, NCT04807348: Chiglitazar Added to Metformin for Type 2 Diabetes

Completed
3
533
RoW
Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage
Chipscreen Biosciences, Ltd.
Type 2 Diabetes
02/23
02/23
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Recruiting
3
672
RoW
PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo
PegBio Co., Ltd.
Type 2 Diabetes Mellitus (T2DM)
11/23
04/25
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

Active, not recruiting
3
408
RoW
HTD1801, berberine ursodeoxycholate, Placebo
HighTide Biopharma Pty Ltd
T2DM (Type 2 Diabetes Mellitus)
03/25
09/25
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
551
RoW
HTD1801, berberine ursodeoxycholate, Placebo
HighTide Biopharma Pty Ltd
Type 2 Diabetes Mellitus
03/25
12/25
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Recruiting
3
888
Europe, US, RoW
Orforglipron, LY3502970, Dapagliflozin
Eli Lilly and Company
Type 2 Diabetes
10/25
10/25
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Completed
3
514
RoW
HLX14, Prolia®
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Postmenopausal
12/23
07/24
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
NCT06633783: A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

Not yet recruiting
3
370
RoW
Semaglutide
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Obesity
05/26
10/26
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

Completed
3
168
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes
10/24
10/24
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
06/25
06/25
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Active, not recruiting
3
405
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteo Arthritis Knee
02/26
03/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Not yet recruiting
2
318
RoW
HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
04/25
04/25

Download Options